肝爽颗粒联合阿德福韦酯治疗肝纤维化的疗效分析

张丰晓; 白雪松

doi:10.3969/j.issn.1001-5256.2014.04.008

肝爽颗粒联合阿德福韦酯治疗肝纤维化的疗效分析

DOI: 10.3969/j.issn.1001-5256.2014.04.008

周口市中心医院感染科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 3590
- HTML全文浏览量: 30
- PDF下载量: 592
- 被引次数: 0
出版历程
- 收稿日期: 2013-05-23
- 出版日期: 2014-04-20

Therapeutic efficacy of Ganshuang granules in treatment of hepatic fibrosis

Department of Infectious Diseases, Zhoukou Central Hospital

摘要

摘要:
目的观察肝爽颗粒抗肝纤维化的疗效。方法选取本院2010年7月-2013年1月收治的68例慢性乙型肝炎肝硬化患者,分为试验组和对照组,每组34例。2组患者均治疗12个月,在单独使用阿德福韦酯治疗6个月后,试验组同时使用肝爽颗粒6个月,而对照组不用肝爽颗料。观察比较2组患者治疗前后肝纤维化血清指标:透明质酸（HA）,层粘连蛋白（LN）,Ⅳ型胶原（CⅣ）,Ⅲ前胶原（PCⅢ）水平及肝脏硬度指标的变化。治疗前后比较采用配对t检验。结果试验组治疗前后血清HA、LN、CⅣ和PCⅢ值分别下降37.5%、34.2%、35.4%和39.9%,肝硬度值下降40.6%,治疗前后差异有统计学意义（t=2.238、2.151、2.148、2.189、2.189,P均<0.05）,而对照组治疗前后上述指标差异无统计学意义。结论肝爽颗粒可改善乙型肝炎肝硬化患者血清肝纤维化标志物水平及降低肝硬度值,表明其有抗肝纤维化疗效。
- 肝炎,乙型,慢性 /
- 肝硬化 /
- 肝爽颗粒 /
- 阿德福韦酯
Abstract:
Objective To observe the therapeutic efficacy of Ganshuang granules in the treatment of hepatic fibrosis.Methods Sixty- eight patients with cirrhosis due to chronic hepatitis B (CHB) were divided into experimental group (n = 34) and control group (n = 34) .Both groups received adefovir dipivoxil for 6 months, and the experimental group received Ganshuang granules additionally for 24 weeks.After treatment, the changes in hepatic fibrosis indices including hyaluronic acid (HA) , laminin (LN) , collagen Ⅳ (C Ⅳ) , and precollagen Ⅲ (PC Ⅲ) , as well as liver stiffness value were evaluated by paired t test.Results In the experimental group, the serum levels of HA, LN, C Ⅳ, and PC Ⅲ were significantly decreased by 37.5%, 34.2%, 35.4%, and 39.9%, respectively (t = 2.238, 2.151, 2.148, and 2.198, P < 0.05 for all) , and the liver stiffness value was significantly cut by 40.6% (t = 2.189, P < 0.05) .However, the control group showed no significant changes in these indices.Conclusion For patients with cirrhosis due to CHB, Ganshuang granules can effectively reduce serum markers of hepatic fibrosis and liver stiffness value and have a good therapeutic efficacy in the treatment of hepatic fibrosis.
- hepatitis B, chronic /
- liver cirrhosis /
- Gan-shuang granules /
- adefovir dipivoxil

HTML全文

参考文献(10)

[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[2]ZHAN GQ, ZHENG SJ, XIE XR, et al.Effects ofα-interferon combined with kushenin on hepatic fibrosis indices in patients with chronic hepatitis B and early liver cirrhosis[J].J Clin Hepatol, 2006, 22 (2) :140-141. (in Chinese) 占国清, 郑三菊, 谢杏榕, 等.α-干扰素联合苦参素对慢性乙型肝炎和早期肝硬化患者的肝纤维化指标的影响[J].临床肝胆病杂志, 2006, 22 (2) :140-141.

[3]YUAN HN, LUO GH, DENG YM, et al.Effects of adefovir dipivoxil combined withγ-interferon on hepatic fibrosis indices in patients with chronic hepatitis B[J].J Clin Hepatol, 2008, 24 (4) :254-255. (in Chinese) 袁海宁, 罗光汉, 邓一呜, 等.阿德福韦酯联合γ-干扰素对慢性乙型肝炎肝纤维化指标的影响[J].临床肝胆病杂志, 2008, 24 (4) :254-255.

[4]XIE SB, YAO JL, ZHENG SS, et al.The relationship between the levels of serum fibrosis marks and morphometric quantitative measurement of hepatic histological fibrosis[J].Chin J Hepatol, 2000, 8 (4) :203-205. (in Chinese) 谢仕斌, 姚集鲁, 郑树森, 等.血清肝纤维化指标水平与肝组织纤维图像分析的关系[J].中华肝脏病杂志, 2000, 8 (4) :203-205.

[5]ZHANG QH, ZHANG CR.Effects of Ganshuang granules on serum markers of hepatic fibrosis and liver function in patients with chronic hepatitis B[J].Guangdong Med J, 2011, 32 (1) :118-119. (in Chinese) 张秋红, 张春瑞.肝爽颗粒对慢性乙型肝炎患者肝纤维化血清标志物及肝功能的影响[J].广东医学, 2011, 32 (1) :118-119.

[6]LIU F, DANG HX, MA JT.Effect of Ganshuang granules on experimental hepatic fibrosis in rats[J].Chin J Integr Tradit West Med Liver Dis, 2005, 15 (5) :286-287. (in Chinese) 刘峰, 党海霞, 马久太.肝爽颗粒对大鼠实验性肝纤维化的影响[J].中西医结合肝病杂志, 2005, 15 (5) :286-287.

[7]YUE LP, MA H, JIA JD.Effects of Ganshuang Keli on gene and protein expression of collagen I, collagenⅢand tissue inhibitor of metalloproteinase 1 in HSC-T6 cells[J].Chin J Integr Tradit West Med Liver Dis, 2007, 17 (2) :85-87. (in Chinese) 岳兰萍, 马红, 贾继东.肝爽颗粒对HSC-T6细胞ColⅡ、ColⅢ、TIMP1基因及蛋白表达的影响[J].中西医结合肝病杂志, 2007, 17 (2) :85-87.

[8]FUNG J, LAI CL, BUT D, et al.Prevalence of fibrosis and cirrhosis in chronic hepatitis B:implications for treatment and management[J].Am J Gastroenterol, 2008, 103 (6) :1421-1426.

[9]MARCELLIN P, ZIOL M, BEDOSSA P, et al.Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B[J].Liver Int, 2009, 29 (2) :242-247.

[10]ZHANG JC, XIONG Q, LI FJ, et al.Application of FibroScan in chronic hepatitis and liver cirrhosis[J].Chin J Integr Tradit West Med Liver Dis, 2010, 20 (5) :301-303. (in Chinese) 张均倡, 熊倩, 黎凤娇, 等.瞬时弹性记录仪Fibroscan在慢性病毒性肝炎及肝硬化中的应用[J].中西医结合肝病杂志, 2010, 20 (5) :301-303.

施引文献

资源附件(0)

访问统计